Navigation Links
Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172
Date:8/14/2008

e (aPTT). The highest infusion dose rate tested, 6.0 mg/kg/hr, resulted in an average ACT per subject ranging from 373 to 414 seconds and an increase of approximately three times baseline. Average PT values per subject ranged from 56 to 92 seconds and had an increase of approximately five times baseline. Average aPTT values per subject ranged from 130 to 178 seconds and had an increase of approximately five times baseline. All measurements were maintained stably throughout the four-hour infusion. Once the infusion ended, the ACT and other coagulation parameters showed a rapid return toward baseline, consistent with the short plasma half-life of NU172 observed in the Phase 1a trial. In addition, NU172 was well-tolerated with no serious adverse events.

"In this study, we were able to identify a dose that meets or exceeds the level of anticoagulation needed for the indications we plan to evaluate, including CABG surgery," said Dr. Ted W. Love, chairman and chief executive officer of Nuvelo. "In addition to supporting our previous proof-of-concept data, the Phase 1b study shows that anticoagulation with NU172 can be maintained for four hours, which is longer than a typical CABG procedure. We are on track to launch a Phase 2 study evaluating NU172 in the fourth quarter of 2008 or the first quarter of 2009."

Approximately 450,000 CABG procedures, 50 million dialysis procedures, and 1.2 million PCIs are performed annually in the U.S. During these procedures, anticoagulants are given to prevent blood clotting. In CABG procedures and often in dialysis, the anticoagulation effect of heparin must be reversed with protamine once the procedure has been completed.

About Aptamers and NU172

Aptamers are chemically synthesized single-stranded nucleic acids that form well-defined three-dimensional shapes, allowing them to bind target molecules in a manner that is conceptually similar to antibodies. Characteristics of aptamers include high specificity and a
'/>"/>

SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172
2. Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172
3. Nuvelo Announces Preclinical Data for NU206 Demonstrating Potent Therapeutic Activity in Oral Mucositis Models
4. Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
5. Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
6. Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
7. Nuvelo Announces Alfimeprase SONOMA-2 Catheter Occlusion Data Presentation Webcast and Conference Call
8. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
9. NewCardio Announces Positive Results From Third Clinical Validation Study
10. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
11. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... -- According to the new research ... Battery, Pneumatic), by Product (Drill, Saw, Stapler, Reamer, ... (Orthopedic, ENT, Oral, Thoracic, Neurology) - Global Forecasts ... Instruments Market is estimated to be worth around ... expected to grow at a moderate CAGR during ...
(Date:11/26/2014)... , Nov. 25, 2014  Medtronic,s ... has been widely discussed in the media ... also creating a stronger leading player in one ... Kalorama Information.  The healthcare market research firm said ... will feature a diverse set of solutions spanning ...
(Date:11/26/2014)... , Nov. 25, 2014  Array BioPharma ... announced that its Chief Executive Officer, ... following upcoming conferences.  The public is welcome ... on the Array BioPharma website:  www.arraybiopharma.com ... 2014Time:1:30 p.m.  Eastern Time Location: Palace Hotel, ...
Breaking Medicine Technology:Powered Surgical Instruments Market Worth $2.1 Billion by 2019 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 3Powered Surgical Instruments Market Worth $2.1 Billion by 2019 4Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 2Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 3
... 2011 UCB, a leading biopharmaceutical company at the forefront ... College of Gastroenterology (ACG) meeting in Washington, D.C. by reinforcing ... disease. At this year,s ACG meeting, a large body of ... in treatment of moderate to severe Crohn,s disease. ...
... Natrix Separations, Inc. announced today new members of its leadership ... Officer and Molly S. McGlaughlin as Vice President of Business ... of Directors since mid-2010, and will continue to hold a ... C. Howie Honeyman, Ph.D. will continue as Senior Vice ...
Cached Medicine Technology:UCB Proudly Reinforces Long-Standing Commitment to Patients and Physicians at American College of Gastroenterology 2011 Annual Scientific Meeting 2UCB Proudly Reinforces Long-Standing Commitment to Patients and Physicians at American College of Gastroenterology 2011 Annual Scientific Meeting 3Natrix Separations Introduces New Leadership Team 2Natrix Separations Introduces New Leadership Team 3
(Date:11/27/2014)... New York (PRWEB) November 27, 2014 ... ) have been filed in a consolidated litigation ... LLP reports. , Documents recently updated in ... records included in the state proceeding, all of ... bipolar disorder and other psychiatric conditions. Many of ...
(Date:11/27/2014)... Nov. 26, 2014 (HealthDay News) -- Most babies and ... cold, the U.S. Food and Drug Administration says. ... given to children younger than 2 because they could ... warned. American adults average about three colds a ... get a cold, parents might want to give them ...
(Date:11/27/2014)... Thanksgiving meals can pose a challenge for people who ... Many traditional Thanksgiving dishes -- such as turkey, ... but "when it comes to pies, stuffing, gravy, etc., ... Safta, director of the Gluten and Allergic Digestive Disorders ... Carolina, said in a center news release. "For ...
(Date:11/27/2014)... The founders of VIM & VIGR, a ... functioning compression socks, are proud to announce the debut of ... Gradient Pressure (TM) knitting technology that is designed to increase ... commitment to adding flair and style to a product that ... the eye of a writer at The New York ...
(Date:11/27/2014)... 2014 Now that Thanksgiving is finally ... launched, Emassagechair.com has announced its eagerly awaited, ... , Negotiating on behalf of their customers, and ... brands, Emassagechair.com has generated significant buzz in the industry ... discounts yet. , Shoppers are excited for significant savings ...
Breaking Medicine News(10 mins):Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 3Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 4Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2Health News:Expert Shares Gluten-Free Thanksgiving Tips 2Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 4
... N.C., July 29 DiaLog, Inc., a ... joint agreement with DeliverMed,Holdings, LLC, an Illinois-based, ... the DiaLog System, promotes compliance,and adherence to ... and their,physicians better manage their disease. DeliverMed ...
... of people world-wide who have contracted a highly resistant ... new drug to treat the infection. , Research ... National Centre in HIV Epidemiology and Clinical Research (NCHECR) ... responded to traditional treatments have had good results from ...
... researchers note risk dissipates quickly once smoking spouse quits , , ... to smokers run a significantly higher risk for experiencing a ... ex-smokers married to men and women who still smoke carry ... former smokers do not appear to bear any higher risk ...
... ASHEVILLE, N.C., July 29 DoctorDirectory.com, ... DAVA Pharmaceuticals, Inc. to,co-market VoSpire ER(R) ... virtual marketing solution. IncreaseRx utilizes,web-based educational ... of thousands of,interested prescribers with targeted ...
... The,Hospitalist Company, Inc. (Nasdaq: IPCM ), a leading ... will report,results for its second quarter 2008 ended June ... close., A conference call to review the results ... August 12, 2008 and will be hosted by Adam ...
... of Patients in National Survey Showed Reduction in Fall ... Strides,the pioneering home balance therapy program from Gentiva Health ... pain and,increasing sensation for thousands of older Americans, according ... released today by the Company., The year-long survey ...
Cached Medicine News:Health News:DiaLog Signs Agreement with DeliverMed to Improve Diabetic Patient Management 2Health News:New therapy for HIV treatment 2Health News:Secondhand Smoke Raises Stroke Risk for Spouses 2Health News:Secondhand Smoke Raises Stroke Risk for Spouses 3Health News:DoctorDirectory to Co-market VoSpire ER(R) with DAVA Pharmaceuticals, Inc. 2Health News:IPC The Hospitalist Company, Inc. to Report Second Quarter 2008 Financial Results 2Health News:Gentiva Safe Strides(R) Home Balance Therapy Program is Reducing Risk of Dangerous Falls and Relieving Pain for Thousands of Older Americans 2Health News:Gentiva Safe Strides(R) Home Balance Therapy Program is Reducing Risk of Dangerous Falls and Relieving Pain for Thousands of Older Americans 3Health News:Gentiva Safe Strides(R) Home Balance Therapy Program is Reducing Risk of Dangerous Falls and Relieving Pain for Thousands of Older Americans 4Health News:Gentiva Safe Strides(R) Home Balance Therapy Program is Reducing Risk of Dangerous Falls and Relieving Pain for Thousands of Older Americans 5
Modular hip abduction system designed to provide superior fit, adjustability and functionality for optimum patient stability, comfort and compliance...
... Harness™ A Pavlik-type harness with greatly ... treatment of congenital hip dysplasia. Color-coded ... and antislip foot pieces.,Color-coded anterior straps ... can be made while the child ...
... in walker design in years. A real step forward! ... surfaces of the foot rest on adaptive areas of ... strike. The footbed in the sole conforms to the ... stability. , ,No leg length discrepancy; Heel height ...
... This low cost walker features a ... innersole. The low profile design minimizes leg ... with D-rings makes strapping quick and easy. ... to accomodate swollen ankles and extra bandaging. ...
Medicine Products: